Inmune Bio, Inc. Aktie News

Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune's CORDStrom™ platform. The article, titled, “Fate and Function of Exogenously Administere...

Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer's disease (AD) and elevated neuroinflammation. The results will be presented at t...

Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer's Disease conference (CTAD), in San Diego, CA on December 1-4, 2025.

INmune Bio, Inc. ( INMB ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Daniel Carlson David Moss - President, CEO, Treasurer, Secretary & Director Mark Lowdell - Chief Scientific Officer & Chief Manufacturing Officer CJ Barnum Cory Ellspermann - Interim Chief Financial Officer Conference Call Participants Denis Reznik - Raymond James Ltd., Research Division Jason Mcca...

BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2025 and provides a business update.

Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC.  The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City.

INmune Bio, Inc. (NASDAQ:INMB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Christopher Barnum - Corporate Participant Daniel Carlson - Corporate Participant David J. Moss - CFO, Treasurer & Secretary Mark William Lowdell - Chief Scientific Officer & Chief Manufacturing Officer Raymond Joseph Tesi - Co-Founder, President, CEO, Chief Medical Officer & Chairman...

INmune Bio (INMB) Q2 Loss Widens 110%